Phage therapy market is growing with over 20 companies developing 22+ therapies
From GlobeNewswire: 2025-01-23 13:00:00
The phage therapy market is on the rise, driven by antibiotic-resistant infections and the need for alternative treatments. 20+ companies are actively developing 22+ phage therapies, including Locus Biosciences, Armata Pharmaceuticals, and more. Clinical trials for promising therapies like LBP-EC01 and AP-PA02 are underway, offering hope for combating multidrug-resistant pathogens.
Regulatory support and increased investments in phage therapies are fueling market growth. Phage therapy, which uses bacteriophages to target specific bacterial pathogens, is gaining traction as an alternative to traditional antibiotics. Companies like Locus Biosciences and Armata Pharmaceuticals are advancing phage-based products, addressing the urgent need for novel treatments for multi-drug-resistant infections.
Phage therapy shows promise in treating antibiotic-resistant bacteria, offering specific targeting and the potential to evolve alongside pathogens. Challenges such as regulatory uncertainties and public perception remain, impacting market adoption. However, ongoing innovation and strategic partnerships are driving the development of effective phage-based treatments, positioning them as key players in infectious disease management.
Key developments in the phage therapy space include promising clinical results from companies like PHAXIAM Therapeutics and Locus Biosciences. Funding initiatives from organizations like the Department of Defense are supporting the clinical development of optimized phage candidates for challenging infections. Companies like BiomX and Armata Pharmaceuticals are also making strategic acquisitions and advancing phage-based therapies to combat bacterial infections effectively.
DelveInsight offers comprehensive insights into the phage therapy pipeline landscape, including drug profiles, clinical trial therapeutics, and collaborations between companies and universities. With a focus on emerging treatments like LBP-EC01 and SNIPR 001, the report provides valuable information on the future of phage-based therapies and their potential impact on infectious disease management.
Read more at GlobeNewswire: Phage Therapies Clinical Trial Pipeline Shows Potential